Anti-IL2RA/ CD25/ IDDM10 monoclonal antibody
Anti-IL2RA/ CD25/ IDDM10 antibody for FACS & in-vivo assay
Go to IL2RA/IL2RA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T03313-Ab-1/ GM-Tg-hg-T03313-Ab-2 | Anti-Human IL2RA monoclonal antibody | Human |
GM-Tg-rg-T03313-Ab-1/ GM-Tg-rg-T03313-Ab-2 | Anti-Rat IL2RA monoclonal antibody | Rat |
GM-Tg-mg-T03313-Ab-1/ GM-Tg-mg-T03313-Ab-2 | Anti-Mouse IL2RA monoclonal antibody | Mouse |
GM-Tg-cynog-T03313-Ab-1/ GM-Tg-cynog-T03313-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IL2RA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T03313-Ab-1/ GM-Tg-felg-T03313-Ab-2 | Anti-Feline IL2RA monoclonal antibody | Feline |
GM-Tg-cang-T03313-Ab-1/ GM-Tg-cang-T03313-Ab-2 | Anti-Canine IL2RA monoclonal antibody | Canine |
GM-Tg-bovg-T03313-Ab-1/ GM-Tg-bovg-T03313-Ab-2 | Anti-Bovine IL2RA monoclonal antibody | Bovine |
GM-Tg-equg-T03313-Ab-1/ GM-Tg-equg-T03313-Ab-2 | Anti-Equine IL2RA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T03313-Ab-1/ GM-Tg-hg-T03313-Ab-2; GM-Tg-rg-T03313-Ab-1/ GM-Tg-rg-T03313-Ab-2; GM-Tg-mg-T03313-Ab-1/ GM-Tg-mg-T03313-Ab-2; GM-Tg-cynog-T03313-Ab-1/ GM-Tg-cynog-T03313-Ab-2; GM-Tg-felg-T03313-Ab-1/ GM-Tg-felg-T03313-Ab-2; GM-Tg-cang-T03313-Ab-1/ GM-Tg-cang-T03313-Ab-2; GM-Tg-bovg-T03313-Ab-1/ GM-Tg-bovg-T03313-Ab-2; GM-Tg-equg-T03313-Ab-1/ GM-Tg-equg-T03313-Ab-2 |
Products Name | Anti-IL2RA monoclonal antibody |
Format | mab |
Target Name | IL2RA |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-IL2RA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T03313 |
Target Name | IL2RA |
Gene ID | 3559,16184,25704,574300,403870,493953,281861,100070292 |
Gene Symbol and Synonyms | CD25,IDDM10,IL-2RA,IL2R,IL2RA,IL2RAC,IMD41,Ly-43,p55,TCGFR |
Uniprot Accession | P01589,P26897,Q5MNY4,O62802,P41690,P12342 |
Uniprot Entry Name | IL2RA_HUMAN,IL2RA_MACMU,IL2RA_RAT,IL2RA_FELCA,IL2RA_CANLF,IL2RA_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | Ovary Cancer |
Gene Ensembl | ENSG00000134460 |
Target Classification | Checkpoint-Immuno Oncology |
The target: IL2RA, gene name: IL2RA, also named as CD25, IDDM10, IL2R, IMD41, TCGFR, p55. The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency. Patients with severe Coronavirus Disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have significantly elevated levels of IL2R in their plasma. Similarly, serum IL-2R levels are found to be elevated in patients with different types of carcinomas. Certain IL2RA and IL2RB gene polymorphisms have been associated with lung cancer risk. [provided by RefSeq, Jul 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.